Almost all reported cases of choroideremia so far have been attributed to functionally null mutations combined with the slow rate of degeneration and small size of the CHM protein coding sequence, which make gene therapy with adeno-associated viral (AAV) vectors an appealing treatment strategy. Here, CHM is linked to choroideremia.